154 related articles for article (PubMed ID: 37467495)
1. The role of the MDM2/p53 axis in antitumor immune responses.
Brummer T; Zeiser R
Blood; 2024 Jun; 143(26):2701-2709. PubMed ID: 37467495
[TBL] [Abstract][Full Text] [Related]
2. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
Ho JNHG; Schmidt D; Lowinus T; Ryoo J; Dopfer EP; Gonzalo Núñez N; Costa-Pereira S; Toffalori C; Punta M; Fetsch V; Wertheimer T; Rittmann MC; Braun LM; Follo M; Briere C; Vinnakota JM; Langenbach M; Koppers F; Shoumariyeh K; Engel H; Rückert T; Märklin M; Holzmayer S; Illert AL; Magon F; Andrieux G; Duquesne S; Pfeifer D; Staniek J; Rizzi M; Miething C; Köhler N; Duyster J; Menssen HD; Boerries M; Buescher JM; Cabezas-Wallscheid N; Blazar BR; Apostolova P; Vago L; Pearce EL; Becher B; Zeiser R
Blood; 2022 Sep; 140(10):1167-1181. PubMed ID: 35853161
[TBL] [Abstract][Full Text] [Related]
3. MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production.
Langenbach M; Giesler S; Richtsfeld S; Costa-Pereira S; Rindlisbacher L; Wertheimer T; Braun LM; Andrieux G; Duquesne S; Pfeifer D; Woessner NM; Menssen HD; Taromi S; Duyster J; Börries M; Brummer T; Blazar BR; Minguet S; Turko P; Levesque MP; Becher B; Zeiser R
Mol Cancer Res; 2023 Aug; 21(8):849-864. PubMed ID: 37071397
[TBL] [Abstract][Full Text] [Related]
4. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity.
Zhou J; Kryczek I; Li S; Li X; Aguilar A; Wei S; Grove S; Vatan L; Yu J; Yan Y; Liao P; Lin H; Li J; Li G; Du W; Wang W; Lang X; Wang W; Wang S; Zou W
Nat Immunol; 2021 Apr; 22(4):460-470. PubMed ID: 33767425
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
[TBL] [Abstract][Full Text] [Related]
6. P53/MDM2 Complex-Based Targeted Strategies in Colon Adenocarcinoma.
Niotis A; Tsiambas E; Dimitroulis D; Sarlanis H; Falidas E; Kavantzas N; Constantinides CA
Acta Med Acad; 2023 Apr; 52(1):24-29. PubMed ID: 37326394
[TBL] [Abstract][Full Text] [Related]
7. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
Kojima K; Konopleva M; Samudio IJ; Shikami M; Cabreira-Hansen M; McQueen T; Ruvolo V; Tsao T; Zeng Z; Vassilev LT; Andreeff M
Blood; 2005 Nov; 106(9):3150-9. PubMed ID: 16014563
[TBL] [Abstract][Full Text] [Related]
8. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
Andreeff M; Kelly KR; Yee K; Assouline S; Strair R; Popplewell L; Bowen D; Martinelli G; Drummond MW; Vyas P; Kirschbaum M; Iyer SP; Ruvolo V; González GM; Huang X; Chen G; Graves B; Blotner S; Bridge P; Jukofsky L; Middleton S; Reckner M; Rueger R; Zhi J; Nichols G; Kojima K
Clin Cancer Res; 2016 Feb; 22(4):868-76. PubMed ID: 26459177
[TBL] [Abstract][Full Text] [Related]
9. Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery.
Kono M; Kumai T; Hayashi R; Yamaki H; Komatsuda H; Wakisaka R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Katada A; Hayashi T; Celis E; Kobayashi H; Harabuchi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3421-3434. PubMed ID: 33866408
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.
Maganti HB; Jrade H; Cafariello C; Manias Rothberg JL; Porter CJ; Yockell-Lelièvre J; Battaion HL; Khan ST; Howard JP; Li Y; Grzybowski AT; Sabri E; Ruthenburg AJ; Dilworth FJ; Perkins TJ; Sabloff M; Ito CY; Stanford WL
Cancer Discov; 2018 Nov; 8(11):1376-1389. PubMed ID: 30115703
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
12. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
13. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
[TBL] [Abstract][Full Text] [Related]
14. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
15. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
Ishizawa J; Nakamaru K; Seki T; Tazaki K; Kojima K; Chachad D; Zhao R; Heese L; Ma W; Ma MCJ; DiNardo C; Pierce S; Patel KP; Tse A; Davis RE; Rao A; Andreeff M
Cancer Res; 2018 May; 78(10):2721-2731. PubMed ID: 29490944
[TBL] [Abstract][Full Text] [Related]
16. Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia.
Hayashi Y; Goyama S; Liu X; Tamura M; Asada S; Tanaka Y; Fukuyama T; Wunderlich M; O'Brien E; Mizukawa B; Yamazaki S; Matsumoto A; Yamasaki S; Shibata T; Matsuda K; Sashida G; Takizawa H; Kitamura T
Nat Commun; 2019 Oct; 10(1):4869. PubMed ID: 31653912
[TBL] [Abstract][Full Text] [Related]
17. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
18. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
20. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.
Manfredi JJ
Genes Dev; 2010 Aug; 24(15):1580-9. PubMed ID: 20679392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]